Is McKesson Corporation Stock Outperforming the Nasdaq?

Core Insights - McKesson Corporation is a leading player in global healthcare distribution, connecting biopharma manufacturers, providers, pharmacies, and patients [1] - The company has a market capitalization of approximately $120.9 billion, indicating its significant presence in the healthcare distribution sector [2] Stock Performance - MCK stock reached a 52-week high of $987.37 in February, with a 11.7% increase over the past three months, outperforming the Nasdaq Composite, which fell by 2.4% [3] - Over the last 52 weeks, MCK stock has surged by 59% and is up 20.4% year-to-date, while the Nasdaq has advanced by 22.2% but declined by 2.5% year-to-date, showcasing McKesson's relative outperformance [5] - The stock has been trading above its 50-day moving average of $865.65 and its 200-day moving average of $776.06 since April 2025, indicating a strong technical structure [5] Financial Performance - In fiscal Q3 2026, McKesson reported revenue of $106.2 billion, an 11.4% year-over-year increase, meeting analyst expectations [7] - Adjusted EPS rose by 16.3% to $9.34, exceeding the Street's estimate of $9.27, reflecting strong financial performance [7] - Growth was driven by strong oncology performance, expanding biopharma services, and continued momentum in North American pharmaceutical distribution [8] - Management raised its full-year non-GAAP earnings outlook, projecting a growth of 17% to 19% compared to the previous year [8] Competitive Positioning - Compared to rival Cencora, Inc., which gained 49.5% over the past 52 weeks and is up 10.2% year-to-date, McKesson has outperformed in both longer-term and year-to-date measures [9]